3. GOOD HEALTH AND WELL-BEING

Citigroup Inc. Has $172,000 Stake in Bausch Health Companies Inc. (NYSE:BHC)

Written by Amanda

Citigroup Inc. lifted its position in shares of Bausch Health Companies Inc. (NYSE:BHCFree Report) by 73.3% during the third quarter, Holdings Channel.com reports. The firm owned 20,820 shares of the company’s stock after purchasing an additional 8,804 shares during the period. Citigroup Inc.’s holdings in Bausch Health Companies were worth $172,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Lazard Asset Management LLC acquired a new position in shares of Bausch Health Companies during the second quarter worth approximately $49,000. FMR LLC raised its position in shares of Bausch Health Companies by 58.3% during the second quarter. FMR LLC now owns 10,057 shares of the company’s stock worth $84,000 after purchasing an additional 3,703 shares during the period. Graham Capital Management L.P. acquired a new position in shares of Bausch Health Companies during the second quarter worth approximately $84,000. Ausdal Financial Partners Inc. purchased a new stake in Bausch Health Companies in the 3rd quarter valued at $86,000. Finally, HighTower Advisors LLC raised its position in Bausch Health Companies by 24.2% in the 1st quarter. HighTower Advisors LLC now owns 10,763 shares of the company’s stock valued at $245,000 after buying an additional 2,100 shares during the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on BHC. Jefferies Financial Group lowered their price target on Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Wednesday, February 7th. Finally, Royal Bank of Canada increased their price target on Bausch Health Companies from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Friday, February 23rd.

View Our Latest Report on Bausch Health Companies

Bausch Health Companies Trading Up 1.1 %

NYSE BHC opened at $10.61 on Friday. The firm has a market capitalization of $3.88 billion, a P/E ratio of -6.55 and a beta of 0.83. The company has a current ratio of 1.30, a quick ratio of 0.94 and a debt-to-equity ratio of 74.20. The business has a fifty day simple moving average of $8.92 and a 200 day simple moving average of $8.05. Bausch Health Companies Inc. has a 12 month low of $5.57 and a 12 month high of $10.80.

Bausch Health Companies (NYSE:BHCGet Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.14. The firm had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.29 billion. Bausch Health Companies had a positive return on equity of 5,147.48% and a negative net margin of 6.76%. The business’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.02 EPS. On average, analysts predict that Bausch Health Companies Inc. will post 3.95 EPS for the current fiscal year.

Bausch Health Companies Profile

(Free Report)

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

Further Reading

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc. (NYSE:BHCFree Report).

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)



Receive News & Ratings for Bausch Health Companies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bausch Health Companies and related companies with MarketBeat.com’s FREE daily email newsletter.

Source: defenseworld.net

Citigroup Inc. lifted its position in shares of Bausch Health Companies Inc. (NYSE:BHCFree Report) by 73.3% during the third quarter, Holdings Channel.com reports. The firm owned 20,820 shares of the company’s stock after purchasing an additional 8,804 shares during the period. Citigroup Inc.’s holdings in Bausch Health Companies were worth $172,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Lazard Asset Management LLC acquired a new position in shares of Bausch Health Companies during the second quarter worth approximately $49,000. FMR LLC raised its position in shares of Bausch Health Companies by 58.3% during the second quarter. FMR LLC now owns 10,057 shares of the company’s stock worth $84,000 after purchasing an additional 3,703 shares during the period. Graham Capital Management L.P. acquired a new position in shares of Bausch Health Companies during the second quarter worth approximately $84,000. Ausdal Financial Partners Inc. purchased a new stake in Bausch Health Companies in the 3rd quarter valued at $86,000. Finally, HighTower Advisors LLC raised its position in Bausch Health Companies by 24.2% in the 1st quarter. HighTower Advisors LLC now owns 10,763 shares of the company’s stock valued at $245,000 after buying an additional 2,100 shares during the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on BHC. Jefferies Financial Group lowered their price target on Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Wednesday, February 7th. Finally, Royal Bank of Canada increased their price target on Bausch Health Companies from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Friday, February 23rd.

View Our Latest Report on Bausch Health Companies

Bausch Health Companies Trading Up 1.1 %

NYSE BHC opened at $10.61 on Friday. The firm has a market capitalization of $3.88 billion, a P/E ratio of -6.55 and a beta of 0.83. The company has a current ratio of 1.30, a quick ratio of 0.94 and a debt-to-equity ratio of 74.20. The business has a fifty day simple moving average of $8.92 and a 200 day simple moving average of $8.05. Bausch Health Companies Inc. has a 12 month low of $5.57 and a 12 month high of $10.80.

Bausch Health Companies (NYSE:BHCGet Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.14. The firm had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.29 billion. Bausch Health Companies had a positive return on equity of 5,147.48% and a negative net margin of 6.76%. The business’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.02 EPS. On average, analysts predict that Bausch Health Companies Inc. will post 3.95 EPS for the current fiscal year.

Bausch Health Companies Profile

(Free Report)

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

Further Reading

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc. (NYSE:BHCFree Report).

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)



Receive News & Ratings for Bausch Health Companies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bausch Health Companies and related companies with MarketBeat.com’s FREE daily email newsletter.

Source: defenseworld.net

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai

Leave a Comment